Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Emicizumab in Healthy Chinese Subjects-Reference-Cited by-同舟云学术

Evaluation of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Dose of Emicizumab in Healthy Chinese Subjects

Published:2020-05-20 Issue:1 Volume:10 Page:30-38
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Li Haiyan¹,Zhang Weijiang²,Petry Claire³,Li Lindong⁴,Fernandez Elena³,Kiialainen Anna³,Feng Sheng⁵,Hsu Wanling⁴,Li Li⁴,Wei Yudong⁶,Schmitt Christophe³

Affiliation:

1. Drug Clinical Trial Center and the Department of Cardiology Peking University Third Hospital Beijing China

2. F. Hoffmann–La Roche Ltd. New York New York USA

3. F. Hoffmann–La Roche AG Basel Switzerland

4. F. Hoffmann–La Roche Ltd Roche Product Development Shanghai Shanghai China

5. F. Hoffmann–La Roche Ltd pRED Roche Shanghai China

6. Drug Clinical Trial Center Peking University Third Hospital Beijing China

Funder

Roche

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.805

Reference25 articles.

1. The Hemophilias — From Royal Genes to Gene Therapy

2. Hemophilia A in the third millennium

3. A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model

4. Anti‐factor IXa/X bispecific antibody ( ACE 910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation

5. Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Inter-Antibody Variability in the Clinical Pharmacokinetics of Monoclonal Antibodies Characterized Using Population Physiologically Based Pharmacokinetic Modeling;Antibodies;2024-07-09

2. Clinical pharmacology of emicizumab for the treatment of hemophilia A;Expert Review of Clinical Pharmacology;2023-08-21

3. From a bispecific monoclonal antibody to gene therapy: A new era in the treatment of hemophilia A;Biomedical Papers;2023-03-15

4. Hemophilia A: Emicizumab monitoring and impact on coagulation testing;Advances in Clinical Chemistry;2023

5. Prophylactic emicizumab for hemophilia A in the Asia‐Pacific region: A randomized study (HAVEN 5);Research and Practice in Thrombosis and Haemostasis;2022-02